Vertex Q3 2026 net income falls 40% year over year to $653.6 million
Bitget2026/11/02 21:03- Vertex Pharmaceuticals' third-quarter 2026 GAAP net income fell 40% year-over-year to $653.6 million, primarily due to Crinetics acquisition expenses.
- Total revenue rose 12% year-over-year to $3.44 billion, primarily driven by continued cystic fibrosis therapy performance and growth in additional disease areas.
- Povetacicept faces a November 30, 2026, FDA target decision date for accelerated approval in IgA nephropathy.
- Full-year 2026 total revenue guidance increased to $13.15 billion–$13.25 billion.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Arbitrage trading is still profitable, but the "easy win" era may be over! Citi warns of narrowing spread risks
The US foreign exchange trading team at Citigroup expects that although carry trade strategies may find it difficult to replicate the impressive returns of the previous period, they will still continue to offer profit opportunities for investors.
BNB falls below $700
Continue fueling AI expenses! Oracle (ORCL.US) reportedly close to selling $10 billions in stocks at an 11% discount, priced at $116.
It is reported that Oracle is about to sell shares worth 10 billions USD at an 11% discount.
Synthetix Protocol DAO transfers 428,000 stolen SNX
Crypto prices
More
